Literature DB >> 14663182

A beta 1-42 induces production of quinolinic acid by human macrophages and microglia.

Gilles J Guillemin1, George A Smythe, Laura A Veas, Osamu Takikawa, Bruce J Brew.   

Abstract

We hypothesized that the tryptophan catabolites produced through the kynurenine pathway (KP), and more particularly the excitotoxin quinolinic acid (QUIN), may play an important role in the pathogenesis of Alzheimer's disease (AD). In this study, we demonstrated that aggregated amyloid peptide A beta 1-42 induced indoleamine 2,3-dioxygenase (IDO) expression and resulted in a significant increase in production of QUIN by human primary macrophages and microglia. In contrast, A beta 1-40 and prion peptide (PrP) 106-126 did not induce any significant increase in QUIN production. These data imply that local QUIN production may be one of the factors involved in the pathogenesis of neuronal damage in AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14663182     DOI: 10.1097/00001756-200312190-00005

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  43 in total

1.  Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study.

Authors:  Vincent Chouraki; Sarah R Preis; Qiong Yang; Alexa Beiser; Shuo Li; Martin G Larson; Galit Weinstein; Thomas J Wang; Robert E Gerszten; Ramachandran S Vasan; Sudha Seshadri
Journal:  Alzheimers Dement       Date:  2017-06-08       Impact factor: 21.566

2.  Synergistic Toxicity of the Neurometabolites Quinolinic Acid and Homocysteine in Cortical Neurons and Astrocytes: Implications in Alzheimer's Disease.

Authors:  Paula Pierozan; Helena Biasibetti-Brendler; Felipe Schmitz; Fernanda Ferreira; Carlos Alexandre Netto; Angela T S Wyse
Journal:  Neurotox Res       Date:  2017-11-09       Impact factor: 3.911

3.  Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.

Authors:  Gregory Oxenkrug; Marieke van der Hart; Julien Roeser; Paul Summergrad
Journal:  Endocrinol Diabetes Metab J       Date:  2017-11-19

Review 4.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

5.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

Review 6.  The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.

Authors:  Ka Ka Ting; Bruce Brew; Gilles Guillemin
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

7.  Characterisation of the expression of NMDA receptors in human astrocytes.

Authors:  Ming-Chak Lee; Ka Ka Ting; Seray Adams; Bruce J Brew; Roger Chung; Gilles J Guillemin
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

8.  Circulating Antibodies to IDO/THO Pathway Metabolites in Alzheimer's Disease.

Authors:  S Duleu; A Mangas; F Sevin; B Veyret; A Bessede; M Geffard
Journal:  Int J Alzheimers Dis       Date:  2010-03-15

Review 9.  Promotion of cellular NAD(+) anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease.

Authors:  Nady Braidy; Gilles Guillemin; Ross Grant
Journal:  Neurotox Res       Date:  2008 May-Jun       Impact factor: 3.911

10.  IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4.

Authors:  Manisha C Yadav; E M E Burudi; Mehrdad Alirezaei; Claudia C Flynn; Debbie D Watry; Caroline M Lanigan; Howard S Fox
Journal:  Glia       Date:  2007-10       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.